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Tissue plasminogen activator (t-PA) is one of the ﬁbrin-speciﬁc serine proteases that play a crucial role in the ﬁbrinolytic system.
The rapid clearance of the drug from the circulation, caused by its active uptake in the liver, has lead to complicated clinical
applications. Diﬀerent forms of plasminogen activators have been developed to treat thrombotic disease. Deletion of the ﬁrst three
domains of t-PA by gene manipulation techniques has shown a signiﬁcant increase in its plasma half life. In order to compensate
the disadvantage of higher bleeding risk, a novel chimeric truncated form of t-PA with 394 amino acids and more ﬁbrin aﬃnity
comparedtothetruncatedformwasdesignedtobeexpressedinChineseHamsterOvarian(CHO)cells.Therecombinantchimeric
plasminogen activator consists of kringle 2 and serine protease (K2S) domains of t-PA, namely GHRP-SYQ-K2S. The level of
expression was found to be 752IU/ml with 566,917IU/mg speciﬁc activity, based on amidolytic activity. The ﬁbrin binding of
this novel chimeric truncated t-PA was 86% of the full length t-PA at a ﬁbrinogen concentration of 0.2mg/ml. This could be a
promising approach with more desirable pharmacodynamic properties compared to existing commercial forms.
1.Introduction
Myocardial infarction (MI) is an irreversible necrosis or
death of heart muscles due to prolonged ischemia [1].
According to the third monitoring report of the World
Health Organization, cardiovascular diseases cause 12 mil-
lion deaths throughout the world each year [2, 3]. Throm-
bolytic drugs play a crucial role in the management
of patients with acute myocardial infarction, pulmonary
embolism, deep vein thrombosis, arterial thrombosis, acute
thrombosis of retinal vessel, extensive coronary emboli, and
peripheral vascular thromboembolism [4]. Recognition of
the importance of ﬁbrinolytic system in thrombus resolution
hasresultedin thedevelopment ofvariousﬁbrinolytic agents
and plasminogen activators (PAs) with diﬀerent pharma-
cokineticandpharmacodynamicproperties[4].Threediﬀer-
ent generations of PAs have been introduced to the market.
The ﬁrst generation agents are Streptokinase and Urokinase.
The second generation agents are Alteplase and Acylated
plasminogen streptokinase activator complex (APSAC). The
third generation agents are Vampire bat plasminogen acti-
vator (BatPA), Reteplase, Tenecteplase, Lanatoplase, and
Staphylokinase [4].
Tissue-type plasminogen activator (t-PA) is the domi-
nant PA involved in ﬁbrinolysis [5]. T-PA is a glycoprotein
with 67kDa, 527 amino acids, which promotes conversion
of plasminogen to plasmin in the presence of ﬁbrin. The
protein molecule is divided into ﬁve structural domains:
ﬁngerdomain(F)followedbyagrowthfactordomain(EGF)
near the N-terminal region and the two kringle 1 (K1)
and kringle 2 (K2) domains. Next to kringle 2 domain is
the serine protease domain with the catalytic site at the C
terminus. Both ﬁnger and kringle 2 bind to the ﬁbrin and
accelerate t-PA activation on plasminogen [6]. However, full
length t-PA has some major disadvantages among which
the rapid clearance from plasma due to the recognition
of structural elements on ﬁrst three N-terminal domains
by certain hepatic receptors is the most important [7–9].2 Journal of Biomedicine and Biotechnology
Furthermore, prokaryotic production and refolding process
of full length form is challenging [10]. These two substantial
reasons, have lead to synthesis of the smallest active molecule
such as Reteplase and Lanatoplase that are commercially
available [4].
Reteplase is a deletion mutant of t-PA with prolonged
half-life, in which the F, EGF, and K1 region of wild
type t-PA molecular have been deleted. Finger domain
is the responsible domain for ﬁbrin aﬃnity. Therefore,
Reteplase has weaker aﬃnity for ﬁbrin and causes more
ﬁbrinogen depletion than full length forms [4, 11, 12].
The chimeric tetrapeptide selection was based on following
evidences. Human ﬁbrinogen can be converted to ﬁbrin
through thrombin-catalyzed release of small peptides from
the amino-terminal segments of the K and L chains that
are named ﬁbrinopeptides A and B, respectively [13, 14].
The tetrapeptide GHRP can interact with a complementary
site on the L lobe of ﬁbrin monomers and prevent poly-
merization [13, 14]. Furthermore, it has been reported that
histidine-16 of the BL chain plays an important role in the
association of ﬁbrin [14–16].
In this study, the ﬁrst three domains of t-PA were deleted
in order to increase half life. The other crucial change made
to the protein was that a chimeric tertapeptide Gly-His-Arg-
Pro (GHRP) with high ﬁbrin aﬃnity, was added upstream
of K2S to compensate for diminished ﬁbrin aﬃnity due to F
domain deletion. Therefore,anovel truncatedformt-PA was
designedtobeexpressedinChinesehamsterovarian(CHO).
This experiment was primarily designed and analyzed based
on in silico analysis of the molecule.
2.MaterialsandMethods
DG44 transfection kit and Zeocin selection marker were
obtained from Gibco-Invitrogen cooperation (CA, USA).
Plasminogen was received from Sigma (MO, USA); Chro-
molize t-PA Assay Kit was purchased from Biopool (Trinity
Biotech plc. Ireland). Rabbit polyclonal antibody to t-PA was
supplied by Abcam (MA, USA) and goat anti rabbit IgG-
HRP conjugated was purchased from Santa Cruz biotech-
nology (CA, USA). All reagents for SDS/polyacrylamide gel
electrophoresis were from Bio-Rad, (CA, USA).
2.1. In Silico Predictions. All of the molecular modeling
and structure visualizations were done on a dual
processor windows-based platform, workstation using
the Deepview/Swiss PDB viewer program version 3.7,
2001 (http://www.expasy.org/spdbv) and VMD 1.8.7
(http://www.ks.uiuc.edu),DPM(doublepredictionMethod)
algorithm [17]. Secondary structure prediction was used
to predict the secondary structure of our novel protein.
Atomic coordinates of kringle 2 and serine protease
domain of t-PA were retrieved from the Protein Data Bank
(http://www.rcsb.org/pdb/cgi) [entries 1tpk and 1bda,
resp.] and 1fzv and 2ﬂh both were used as templates for
the 7 amino acid chimeric part: GHRP-SYQ. The 1fzv
and 2ﬂh entries were chosen since they had GDRPSY
and PSYQ in their sequence, respectively, and their pdb
ﬁles did not cause any problem. To produce theoretical
chimeric truncated t-PA using above templates a model was
designed by Modeller 9v1, via automodel package. Energy
minimization was done by GROMOS96 implementation of
Swiss-Pdbviewer http://www.igc.ethz.ch/GROMOS/index).
The Ramachandran plots analysis was performed by
RAMPAGE online Ramachandran plot analysis software
(http://mordred.bioc.cam.ac.uk/∼rapper/rampage).
2.2. Construction of Desired Gene Cassette Using Splicing by
Overlap Extension PCR (SOEing-PCR). Full-length human
t-PA (GenBank accession number 101047) was ampliﬁed
using the CHO 1–15 cell line (ATCC-CRL 9606) genomic
DNA and cloned into pTZ57R during our previous work
[18]. The general mechanism of SOE is illustrated in
(Figure 1). The segments to be joined; fragment AB: signal
sequence from upstream of t-PA full length gene and
fragment CD: K2S from downstream of the gene) are
ampliﬁed in separate PCRs (“1” and “2”). The primers
used to be “SOEn” (B: CGGCCTATGACCTCTAGCTC-
CTCTTCTGAATCGGGandC:GGTCATAGGCCGTCATAT-
CAAGGAAACAGTG) are made partially complementary to
one another and also include nucleotides to be inserted
(GHRP-SYQ) between signal sequence and K2S. Forward
and reverse primers are as follows: A, GATCTGCCACCATG-
GATG, and D, TGGTCTAGATCACGGTCGCATGTTG. The
PCR products of these ﬁrst reactions overlap via their
homologous sequences at the ends which contain the desired
insertion (GHRP-SYQ) as well. The three domains were
deleted and a 21bp fragment was inserted simultaneously.
The products of the ﬁrst step are mixed in a SOE reac-
tion (reaction 3), and subjected to repeated rounds of
denaturation, reannealing, and primer extension by DNA
polymerase. By presence of the appropriate primers (“A” and
“D”) in the reaction, the recombinant product is formed.
The ﬁrst step PCR reactions was done in the following
conditionsforABandCDfragments:ﬁrstreaction:1μLt-PA
DNA (22.7ng/μL), 0.2mM DNTP, 1μLp r i m e rA( 0 . 4μM),
2μLp r i m e rB( 0 . 4 μM), 21μLB u ﬀer, and 2mM MgSO4;
Second reaction: 1μL t-PA DNA (26ng/μL), 0.2mM DNTP,
1μLp r i m e rD( 0 . 4 μM), 2μLp r i m e rC( 0 . 4 μM), 21μL
Buﬀer, and 2mM MgSO4. The SOEing PCR reaction was as
follows: Fragment AB as the ﬁrst template 1μL( 5 4n g / μL)
a n df r a g m e n tC Da ss e c o n dt e m p l a t e1μL( 5 8n g / μL) were
combined and the PCR reaction was run without the
presence of primers for 3 cycles (94◦C, 4min, 94◦C, 1min,
and 72◦C 1min), then the procedure completed in 94◦C
1min,68◦C1min,72◦C1minfor30cycles,andaﬁnal5min
72◦C extension time in the presence of A and D primers.
2.3. Construction of Expression Vector pTracer-SV40-GHRP-
SYQ-K2S. After performing SOEing PCRs, the SOEn
1200bpgenewascleanedupbyaQIAquickPCRPuriﬁcation
kit (Qiagen Germany), cloned in an intermediate vector
pJET1.2/blunt Cloning Vector via CloneJET PCR Cloning
Kit (Fermentas, Vilnius, Lithuania) based on the manufac-
turer’s procedures. After conﬁrming the proper sequence
arrangement by bidirectional sequencing, two upstream andJournal of Biomedicine and Biotechnology 3
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Figure 1: Schematic overview of primer designed for SOEing PCR process.
downstream BglII restriction sites of pJET were used due
to accomplish cloning into CHO expression vector, EcoRV
site in pTracer-SV40’s. BglII sticky ends were converted
to blunt ends using CloneJET PCR Cloning Kit DNA
blunting enzyme. The recombinant pTracer-SV40-chimeric-
truncated-t-PA plasmid was puriﬁed by EndoFree Plasmid
Mega kit (Qiagen Germany) and the presence and right
orientation of the gene was conﬁrmed by SmaI restriction
enzyme digestion (results not shown).
2.4. CHO Transfection and Transient Expression. DG44
Transfection Kit (GIBCO Invitrogen USA) was utilized to
transfect DG44 CHO cells by LIPOFECTAMINE 2000 CD,
b a s e do nm a n u f a c t u r e r ’ s1 2w e l lp l a t e ’ sp r o t o c o l .T r a n s f e c t e d
cellswereexaminedunderﬂuorescentmicroscopeGFPﬁlters
with excitation wavelength of 400nm and emissions wave-
length of 510nm for transient expression of pTracer SV40
GFP protein which is partially correlated with t-PA gene
expression.
2.5. Stable Expression. Zeocin sensitivity of CHO DG44 cells
was determined based on pTracer-SV40 manual guide. The
pTracer-SV40-chimeric-truncated t-PA was linearized from
BglII restriction site. Linierized plasmid was then transected
to the cells by DG44 transfection kit, and stable integrants
were selected above the predetermined Zeocin sensitivity
concentration (500μg/mL).
2.6. SDS-PAGE and Western Blot Analysis. Supernatants
fromstabletransfectedCHOculturemediumwereharvested
and concentrated using Amicon ﬁltering system (Millipore,
USA). SDS-PAGE was carried out in a 12% resolving poly-
acrylamide gel according to the Laemmli method. Western
blot analysis of culture media was performed according to
Sambrook et al. Electroblotting was performed in a semidry
blotting system. Proteins were transferred to a nitrocellulose
membrane, and antigen-antibody complexes were visualized
by DAB-HRP system. Primary polyclonal rabbit anti-t-PA
antibody (Abcam. USA) were diluted 1/1000, the secondary
antibody, peroxidase conjugated goat antirabbit antibody
(Santa Cruz. USA) was used in a 1/1500 dilution.
2.7. Copolymerized Plasminogen Polyacrylamide Gel Elec-
trophoresis. An 11% resolving polyacrylamide gel was
copolymerized with plasminogen and gelatin as previously
described by Heussen and Dowdle [19]. The stacking gel
was prepared as 4% concentration without plasminogen
and gelatin. Electrophoresis was performed at 40◦Ca ta
constant current of 8mA. The residual SDS in gel slab was
removed after a gentle shaking at room temperature for 1h
in 2.5% Triton X-100. Then, the gel slab was incubated in
0.1M glycine-NaOH, pH 8.3, for 5h at 37◦C. Finally, the
gel slab was stained and destained by standard Coomassie
brilliant blue (R-250) dying system. The location of the
peptide harboring enzymatic activity was not stained by dye
in contrast to blue-paint background.
2.8. Puriﬁcation. The one-step puriﬁcation procedure was
performedusingHiTrapBenzamidineFF(highsub)column.
The column is speciﬁed for the puriﬁcation of serine pro-
teases. The buﬀers referred to are as follows: 0.05mMTris-
HCL, 0.5M NaCl, PH 7.4 was used as binding and wash
buﬀer. Elution buﬀers were performed using a step gradient
of 0.5M NaCl, 10mM HCl, and PH 2.0, and 1M NaCl,
10mM HCl, and PH 2.0. Aﬃnity bound substances were
eluted by increasing the salt concentration. Step 1: after
washing the column with 5 columns of distilled water to
remove storage buﬀer, the column was equilibrated with
5-column volumes of binding buﬀer. Step 2: cell culture
conditioned media was ﬁltered through a 0.45μm ﬁlter and
loaded to the column at the same ﬂow rate (1mL/min). Step
3: the column was again washed with 10 column volumes of
binding buﬀer until no material appeared in eluted fraction.
Step 4: the t-PA was eluted from the column with 5mL
of each salt concentration (0.5 and 1M NaCl ) of elution
buﬀers. The pH and conductivity of the buﬀers were such
thatthet-PAboundselectivelytothecolumnelectrostatically
while the bulk of the other nonserine protease proteins
material did not bind to the resin and were removed in the
column ﬂow through.
2.9. Quantiﬁcation (Amidolytic Activity Test). Biopool Chro-
molize t-PA Assay Kit is a biofunctional immunosorbent
assay based on capturing t-PA by sp-322 monoclonal anti-
bodies coated on the microtest wells. After fulﬁlling, the
steps from the kit’s manual samples were read at 405nm and
492nm. Absorbance at 492nm is measured and subtracted
from 405nm. Various dilutions of each sample were assayed.
The amount of developed colour is proportional to the
amount of t-PA activity in the sample.4 Journal of Biomedicine and Biotechnology
2.10.FibrinBindingAssay. Thebindingoft-PAswasassessed
by previously reported methods [20–22]. Brieﬂy, various
concentrations of ﬁbrinogen (0–0.3mg/mL) were mixed
with bovine thrombin (0.5U/mL) in buﬀer (0.05M Tris-
HCl, pH 7.4, 0.12M NaCl, 0.01% Tween 80, and 1mg/mL
bovine serum albumin) to form ﬁbrin clots. After incubating
the mixture for 30min at 37◦C equal units (3000unit) of
truncated or full length t-PA were added. The mixture was
incubated for 30min at 37◦C, and the clot was removed by
centrifugation (15min, 13000rpm, 4◦C; Sigma 202 MD).
The amount of enzyme bound to ﬁbrin was calculated from
the diﬀerence of the total amount of enzyme and the free
enzyme in the supernatant, as determined by ELISA. In the
ELISA assay, 100 microliters of full length and truncated t-
PA are pipetted into each well. The covered plate is incubated
for 15 minutes at 37◦C, and the reaction is started by
the addition of 100 microliters of a plasminogen/S-2251
mixture which contains two parts 10mM S-2251, one part
plasminogen solution (1mcg/mL), and seven parts assay
buﬀer. The mixture is prepared immediately prior to use.
(Assay buﬀer is Tris saline prepared by dissolving 605mg
Tris in 800mL distilled water and adjusting the pH to 8.8
with 6 normal HC1, then dissolving 5.84 grams NaCl and 0.1
grams Triton X-100 into the buﬀer and diluting to 1000mL.)
The absorbance (405nm) is then measured at 20, 40, and 60
minutes [17, 23, 24].
3. Results
3.1. In Silico Predictions
3.1.1. Secondary Structure Prediction. Double prediction
method (DPM) algorithm [17] was used to predict sec-
ondary structure of the chimeric truncated t-PA and full
length protein. Percentage of alpha helix, extended strand,
beta turn and random coil were 27.66, 26.9, 13.45, and 31.9
in chimeirc-truncated t-PA and 26.87, 26.69, 15.84, and 30.6
in full-length t-PA, respectively. As could be expected, no
signiﬁcant diﬀerences in secondary structure were detected
between chimeric truncated t-PA and full-length protein.
3.1.2. Tertiary Structure Prediction. Chimeric-truncated-t-
PA (GHRP-SYQ-K2S) was successfully modeled via MOD-
ELLER 9V1 automodel package using templates mentioned
in Section 2 (Figures 2(a) and 2(b)). We superimposed
chimeric-truncated model both on K2 (1TPK) and S
(1BDA). The predicted model for chimeric-truncated t-
PA in this study showed desirable calculated RMSDs after
superimposing to the 1tpk (2.79, 2.64, and 2.94 for A, B, and
Cchains,resp.)andalso0.53aftersuperimposingtothe1bda
structure. As RMSD values below 2 were acceptable in our
criteria, the results of 1bda superimposing which represents
functional domain of t-PA showed that the mentioned
genetic manipulations do not change the main structure
drastically. Therefore, it is predicted that designed novel
molecule would not loose thrombolytic activity. The results
of Ramachandran plot analysis showed desirable results of
almost 1% of residues in outliner region for both K2S and
chimeric form which is acceptable in this software’s criteria.
3.2. Preparing Desired Cassette Gene
3.2.1. SOEing PCR. We succeeded in deleting the ﬁrst three
domains of t-PA (Finger, EGF, and K1), and juxtaposing
signal peptide upstream of K2S. A 21 base pare DNA
sequence, related to GHRP-SYQ amino acids, was inserted
between signal sequence and K2S domains by using 2 sets of
primers in one SOEing reaction, simultaneously. The PCR
products for the forward and reverse reactions which were
used to generate the chimeric-truncated gene are shown in
Figure 3. The PCR products with 134bp (lane1), 1089bp
(lane3), and 1223bp (lane4) represent signal sequence-
GHRP, GHRP-SYQ-K2S and full-length mutated sequence
(signal sequence + GHRP + SYQ + K2S), respectively. These
ﬁndings are in accordance with the theoretical calculated
lengths.
3.2.2. Construction of Truncated-t-PA-pTracer-SV40 Fusion
Plasmid. The full-length fused fragment was success-
fully ampliﬁed and ligated into the pTracer-SV40 vec-
tor (Invitrogen-USA) using EcoR-V and BglII restriction
enzyme sites on vector and inserted gene, respectively.
Furthermore, ligation was conﬁrmed by digestion with
restriction endonucleases (data not shown). To conﬁrm
absence of any kind of mutation during gene manipulation
and also to determine desired chimeric conjunction, the
clonedgenewassequenced.Thesequenceshowedthedesired
chimericconjunctionatthe36thtothe39thresidue,andﬁrst
3 amino acids of native t-PA, exactly before K2S fragment
and just after signal sequence (data not shown).
3.3. Transfections
3.3.1. Transient Expression. After transfection of CHO cells
with nonlinear plasmid, the cells were allowed to recover for
24 to 48 hours and then assayed by ﬂuorescence microscopy.
The results showed 10%–20% transfection eﬃciency (data
not shown).
3.3.2. Stable Transfection. As mentioned in Section 2,
chimeric truncated t-PA was cloned in pTracer-SV40 expres-
sion vector for transformation. The positive clones were
selected based on Zeocin resistance and PCR ampliﬁcation
of the integrated t-PA gene was performed. The proper
band related to chimeric truncated t-PA gene is shown in
Figure 4.
3.4. Expression Analysis. Expression of chimeric truncated t-
PA gene is shown in Figure 5(a); a 43kd protein bond is
shown in lane 1 Figure 5(a).T h i sb a n di sr e l a t e dt oc h i m e r i c
truncated t-PA based on theoretical calculations, 359 amino
acid sequences. The full-length t-PA protein is shown in lane
2,65kDa.Thisﬁndingwasconﬁrmedusingantibodyagainst
t-PAproteininWesternblotanalysis,Figure 5(b).Lane1and
2i nFigure 5(b) belong to diﬀerent clones of the chimeric
truncated t-PA, and lane 3 is commercially available t-PA,
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Figure 2: Cartoon Ribbon display in VMD 1.8.7 program for two diﬀerent views of GHRP-SYQ-K2S modeled with MODELLER 9V1. (a)
Left back view for a ribbon model of GHRP-SYQ-K2S modeled with MODELLER 9V1 automodel package (chimeric part shown in orange).
(b) Left bottom view for a ribbon model of GHRP-SYQ-K2S modeled with MODELLER 9V1 automodel package; purple: alpha helix, blue:
3 10 helix, yellow: extended beta, tan: bridge beta, cyan: turn, and white: coil.
1234 5
134bp
1089bp 1223bp
Figure 3: Gel-electrophoresis analysis of PCR-products of chimeric
truncated t-PA on 1% agarose gel. Lane 1: 134bp forward PCR
product; signal sequence + GHRP. Lane 3: 1089bp Reverse PCR
product; GHRP-SYQ-K2S. Lane 4: 1223bp full-length SOEn PCR
product signal sequence + GHRP-SYQ-K2S. Lane 2&5: 1kb ladder.
1 23 4
Figure 4: Gel-electrophoresis analysis of PCR products performed
on stable transfected CHO cells and control cell line. Lane 1:
PCR product from nontransfected CHO genomic DNA. Lane 2:
PCR product from transfected CHO genomic DNA. Lane 3: PCR
product from another transfected CHO genomic DNA. Lane 4: 1kb
ladder
43kd
65kd
(a)
1 2 3
43kd
65kd
(b)
Figure 5: (a) SDS-PAGE analysis from supernatant of transfected
CHO cells, 12% gel-coumasei blue stained. Right line: truncated t-
PA CHO cell culture medium. Middle line: full length t-PA. Left
line: protein marker. (b) Western Blot analysis from supernatant of
transfectedCHOcells.Lane1&2:chimerictruncatedt-PACHOcell
culture medium. Lane 3: full length t-PA.
3.5. Electrophoretic Activity Analysis. Using the standard
electrophoretic procedure as described in Section 2, the
supernatants of cultured media of transfected CHO cells
showed enzymatic activity as clear zones of proteolysis
against a blue background of undegraded stained gelatin.
As shown in Figure 6, clear zone for truncated form is
similar to what is demonstrated in the positive control well,
commercial t-PA medicine .6 Journal of Biomedicine and Biotechnology
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Figure 6: Identiﬁcation of plasminogen activators and proteases
in 11% polyacrylamide gel containing gelatin. The gel contains
11% polyacrylamide, 0.1% SDS, 0.1% copolymerized gelatin and
13μg/ml plasminogen. Samples were electrophoresed at a constant
c u r r e n to f8m Ai n4 ◦C temperature as follows: Lane3 Reference
protein mixture lane 1: Actylase (full length t-PA), lane 2: Actylase
+polyclonal anti-t-PA rabbit antibody, lane 4: negative control, lane
6: transfected CHO cells supernatant, lane 5: transfected CHO cells
supernatant+anti-t-PA antibody. After electrophoresis the gels were
washed in Triton X-100, incubated in glycine-NaOH buﬀer at 37◦C
for3handﬁxed,stained,anddestainedasdescribedunderMethod.
3.6. Quantitative Analysis. Our utilized aﬃnity puriﬁcation
procedure resulted in more than 80% puriﬁed samples (data
not shown). For quantitative determination of human tissue
plasminogen activator activity in puriﬁed supernatant sam-
ples of transfected CHO cell, a biofunctional immunosor-
bent assay was performed. Based on Biopool’s Chromolize
t-PA assay kit, amidolytic unit on days 7 and 9 of culture
was found to be 540unit/mL and 752unit/mL, respectively.
This expression is much higher than what has been shown
previously in E. coli, 7unit/mL [25]. The estimated speciﬁc
activity was 566,917unit/mg. This activity is comparable to
what is reported for full length t-PA: 580,000unit/mg and
truncated form: 575,000unit/mg.
3.7. Fibrin Aﬃnity Assay. As it is illustrated in Figure 7,i n
0.2mg/mL ﬁbrinogen concentration the chimeric truncated
protein (GHRP-SYQ-t-PA) showed a ﬁbrin aﬃnity of 38%,
compared to full length form with 44%. In 0.3mg/mL
ﬁbrinogen, chimeric-truncated form had 46% aﬃnity to
ﬁbrin compared to full-length form with the value of
53%. Therefore, assuming that the control full-length form
has 100% of ﬁbrin aﬃnity, the chimeric-truncated form
represented 86% of ﬁbrin aﬃnity of full length protein.
4. Discussion
Plasminogen activators (PAs) are used in treating cardiovas-
cular and cerebrovascular obstructions [12, 26–28]. Apart
from laborious production and refolding process, short
plasma half life has complicated full-length t-PA’s clinical
application [8, 29, 30]. Deletion-variants of t-PA such as
Lanotaplase and Reteplase are nonglycosylated truncated
forms constructed to increase plasma half life [4, 31, 32]. It
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Figure 7: Binding to ﬁbrin clots. Diﬀerent concentrations of ﬁbrin
were incubated with full length () or chimeric-truncated t-PA (∗)
Data represent means obtained from three experiments.
seemsthatdeletionoftheseregionscouldbeanadvantage.In
addition, presence of GHRP amino acids sounds beneﬁcial
for improving ﬁbrin aﬃnity [16]. Taking advantage of
these two factors a chimeric truncated form of t-PA was
designed based on in silico analysis. The analysis showed
that the molecule preserves the crucial regions of full length
t-PA. As previously reported the ﬁrst 3 amino acids of
t-PA (SYQ) are important for the protein activity, and
we decided to conjugate this part to the K2S (functional
domain) the same as what is done in Reteplase (truncated
form of t-PA). This truncated form has proven to be active
while SYQ is juxtaposed to K2S domain without any other
interfering amino acids. So, we proposed that SYQ-K2S
arrangement is responsible for the serine protease activity.
On the other hand, the aim of this study was to improve
some pharmacodynamic properties of an existing truncated
t-PA (Reteplase). So, in order to compare our proposed
form with the previous one we should keep all other parts
intact; that is, SYQ-K2S should have been persevered to
observe the sole eﬀect of GHRP addition in ﬁbrin-binding
aﬃnity. The chimeric GHRP was designed to increase ﬁbrin
aﬃnity compared to Reteplase. We proposed that in order
to have better access to ﬁbrin cloths in purpose of improved
interaction of the chimeric protein with ﬁbrin cloths it is
bettertohavethechimericGHRPsituatedintheN-terminus
and not between other residues the same as what is done in
Jiao et al.’s article.
Apart from cell line development [33] and synergism
strategies [33–35] improving eﬃcacy by protein engineering
is greatly promising. Principal focus of these eﬀorts is
eliminating regions to reduce the size of molecule and
increase half life. Deleting F, E, and k1 domains reduces
both ﬁbrin binding and ﬁbrin enhancement of plasminogen
activator [36, 37]. In order to compensate this disadvantage,
inserting additional ﬁbrin-binding sites into the molecule
enhances speciﬁty.
Our chimeric-truncated form showed desirable protein
stability based on Ramachandran plot predictions andJournal of Biomedicine and Biotechnology 7
RSMD values. In Ramachandran plot analysis, nearly, 1%
of the residues, including residues 4 and 5 were found
to be in outliner region. Given that the residues 4 and 5
are representing an unnatural, chimeric junction, less than
1% of residues are not modeled well which is favorable
compared to similar strategies [38]. Additionally, the best
RMSD value was the result of superimposing our model on
1BDA template which consists of 300 amino acids; 76% of
total protein residues and the active site as well.
Theexperimentalanalysisconﬁrmedourinsilicoanalysis
ﬁndings. Chimeric-truncated t-PA was expressed in CHO
DG44 cells. The level of expression was found to be
752IU/mLinoptimizedcondition.Thislevelofexpressionis
promising compared to enzymatic activity of produced t-PA
in E. coli (3–7IU/mL) [10], nonmodiﬁed rCHO (50IU/mL)
[37], Aspergillus nidulans (0.1μg/mL) [39], or Leishmania
tarentolae (70IU/mL) [18].
Enhancing productivity of cell lines is crucial for
reducing costs. Among nonrecombinant mammalian cell
producers Bowes melanoma cell line is perhaps the best
choice with the productivity more than 30IU per 106 cells
per day (0.1mg/L conditioned medium) [37, 40]. Epithelial
cells like guinea pig ear keratocytes (GPK) have yields of
production ranged over 5–10mg/L from perfusion cultures
with (7–10)×106 anchored cells per milliliter [37, 40].
Between recombinant mammalian cells with inserted copies
of human t-PA gene, mouse C127 ﬁbroblasts (with 55mg/L
production rate ), rat myeloma (with 52mg/L production
rate), and CHO cells (with 65mg/L production rate) in
perfusedorfed-batchsystemsareworthmentioning[37,41].
Considering other recombinant cultures, Saccharomyces
cervisiae has a low yield of production with extensive hyper
glycosylated and heterogenic forms [42]. Bacterium Escher-
chia coli produces t-PA as inclusion bodies consisting 5%–
10% of cell proteins [43]. Because of low recovery of active t-
PA from inclusion bodies, bacterial production process does
not seem feasible. In one study, coexpressing of native or het-
erologous cysteine oxidoreductases increased expression lev-
els to 180μg/L [44]. Despite the complexity of renaturation
from inclusion bodies [45], E. coli fermentation is far less
demanding than animal cell culture. Furthermore, glycosyla-
tion is not necessary for biological activity; also nonglycosy-
lated forms show increased plasma half lives, hence, t-PA.
Production in bacteria is still desirable and perhaps
become feasible either with advances in renaturation meth-
ods or with reduction in number of disulﬁde bonds via
protein engineering. The suggested chimeric-truncated form
is promising due to potential of production in prokaryotic
systems similar to its nonglycosylated commercial relative,
Reteplase.
We designed our cassette gene by having t-PA signal
sequence upstream of chimeric-truncated molecule via
SOEing PCR in order to take advantage of proper folding
and glycosylation in CHO. Diﬀerent sizes of templates is
a problematic matter in applying SOEing PCR procedure
and closer template sizes are preferred in this strategy [46].
Here, owing to appropriate primer design, two remarkably
diﬀerent sizes of templates, 134bp and 1089bp, were
successfully sued by using sensible molar ratios of both
templates and primers. In addition, deletion and insertion
were performed concurrently.
The protein migrated with an apparent molecular mass
of 43kDa on SDS-PAGE; also, an 86kDa bond was obvious
while western blotting was performed. All the dimer form
was converted to monomer form by dissolving the protein
in 8M urea, and just one bond at 43KD was observed on
Western Blot (data not shown). These data conﬁrmed that
the doubled molecular mass size could be due to aggregation
of truncated t-PA.
Biological activity was tested with electrophoretic
zymography analysis. Previous studies have shown that the
main extracellular protease band secreted by the CHO was
a p p r o x i m a t e l y9 2o r9 5 K D a[ 47, 48]. This indicates that
the extra higher size bonds are probably from CHO itself.
However, presence of an obvious band of almost 43KDa and
its drastic diminish after inhibition by antibody conﬁrms
that the proteolytic activity was exclusively due to t-PA
and not other probably existing serine proteases. As it is
shown in Section 3, (lane 5 of Figure 6), signiﬁcant decline
of proteolytic zone in the presence of special t-PA antibody is
apparent. The degree of inhibition by antibody is dependent
uponthet-PAconcentration,butisneverthelessdramatically
reduced when compared to the equivalent concentration in
samples without antibody [19, 48].
Both ﬁbrin speciﬁty and ﬁbrin aﬃnity are touted as
desirablepropertiesinPAs[21,23].Theﬁbrin-speciﬁcagents
are much more likely to bind to ﬁbrin bound plasminogen
as opposed to free plasminogen. Therefore, the lack of
systemicplasminemialimitssystemicﬁbrinogenolysis,which
is associated with bleeding complications [32]. Reteplase was
initially thought to have desired ﬁbrin-speciﬁty [32], but in
practice it was less ﬁbrin speciﬁc than full-length form [4].
Subsequently, higher frequency of bleeding was reported by
Reteplase [4]. Previous studies showed that Reteplase has the
in vitro ﬁbrin binding equal to 30% of that of full-length
form[12].Theﬁbrin-bindingexperimentdemonstratedthat
chimeric-truncated t-PA had 86% of ﬁbrin-binding capacity
of full-length form, Actylase, suggesting that our novel
protein could be targeted to ﬁbrin clot with GHRP. However,
considering controversies now besetting advantages of ﬁbrin
aﬃnity, to what extent this increase of ﬁbrin aﬃnity is
beneﬁcial for drug is now under investigation in our group
for further steps of research. Nevertheless, as the chimeric
protein has yet less ﬁbrin aﬃnity than full-length one, it can
be said that this degree of increase is not at least pernicious.
Acknowledgment
This paper was supported by a grant from the Pasteur
Institute of Iran.
References
[ 1 ]E .B o e r s m a ,N .M e r c a d o ,D .P o l d e r m a n s ,M .G a r d i e n ,J .V o s ,
and M. L. Simoons, “Acute myocardial infarction,” The Lancet,
vol. 361, no. 9360, pp. 847–858, 2003.
[2] R. Beaglehole, R. Saracci, and S. Panico, “Cardiovascular
diseases: causes, surveillance and prevention,” International
Journal of Epidemiology, vol. 30, no. 1, pp. S1–S4, 2001.8 Journal of Biomedicine and Biotechnology
[3] “Health system:Improving performance,” The World Health
Report, World Health Organiztion, Geneva, Switzerland,
2000.
[4] D. B. Baruah, R. N. Dash, M. R. Chaudhari, and S. S.
Kadam, “Plasminogen activators: a comparison,” Vascular
Pharmacology, vol. 44, no. 1, pp. 1–9, 2006.
[5] S. M. Camiolo, S. Thorsen, and T. Astrup, “Fibrinogenolysis
and ﬁbrinolysis with tissue plasminogen activator, urokinase,
streptokinase-activated human globulin, and plasmin,” Pro-
ceedings of the Society for Experimental Biology and Medicine,
vol. 138, no. 1, pp. 277–280, 1971.
[6] D. C. Rijken, “Relationships between structure and function
of tissue-type plasminogen activator,” Klinische Wochenschrift,
vol. 66, supplement 12, pp. 33–39, 1988.
[7] J. Kuiper, A. Van’t Hof, M. Otter, E. A. L. Biessen, D. C. Rijken,
and T. J. C. van Berkel, “Interaction of mutants of tissue-
type plasminogen activator with liver cells: eﬀe c to fd o m a i n
deletions,” Biochemical Journal, vol. 313, no. 3, pp. 775–780,
1996.
[ 8 ]J .J .E m e i s ,C .M .v a nd e nH o o g e n ,a n dD .J e n s e ,“ H e p a t i c
clearanceoftissue-typeplasminogenactivatorinrats,”Throm-
bosis and Haemostasis, vol. 54, no. 3, pp. 661–664, 1985.
[9] A. Hotchkiss, C. J. Reﬁno, C. K. Leonard et al., “The
inﬂuence of carbohydrate structure on the clearance of
recombinant tissue-type plasminogen activator,” Thrombosis
and Haemostasis, vol. 60, no. 2, pp. 255–261, 1988.
[10] D. Pennica, W. E. Holmes, and W. J. Kohr, “Cloning and
expression of human tissue-type plasminogen activator cDNA
in E. coli,” Nature, vol. 301, no. 5897, pp. 214–221, 1983.
[11] C.Philippe,“Biotechnologyforcardiovasculardiseases,”2007,
www.bioimpact.org.
[12] W. D. Weaver, “The role of thrombolytic drugs in the
management of myocardial infarction. Comparative clinical
trials,” European Heart Journal, vol. 17, pp. 9–15, 1996.
[13] K. Bailey, F. R. Bettelheim, L. Lorand, and W. R. Middlebrook,
“Action of thrombin in the clotting of ﬁbrinogen,” Nature, vol.
167, no. 4241, pp. 233–234, 1951.
[14] N. Hasegawa and S. Sasaki, “Location of the binding site “b”
for lateral polymerization of ﬁbrin,” Thrombosis Research, vol.
57, no. 2, pp. 183–195, 1990.
[15] B. V. Pandya, J. L. Gabriel, J. O’Brien, and A. Z. Budzynski,
“Polymerization site in the βchain of ﬁbrin: mapping of the
B β 1–55 sequence,” Biochemistry, vol. 30, no. 1, pp. 162–168,
1991.
[16] J. Jiao, M. Yu, and B. Ru, “Characterization of a recombinant
chimeric plasminogen activator with enhanced ﬁbrin bind-
ing,” Biochimica et Biophysica Acta, vol. 1546, no. 2, pp. 399–
405, 2001.
[17] G. Deleage and B. Roux, “An algorithm for protein secondary
structure prediction based on class prediction,” Protein Engi-
neering, vol. 1, no. 4, pp. 289–294, 1987.
[18] M. Soleimani, F. Mahboudi, N. Davoudi et al., “Expression
of human tissue plasminogen activator in the trypanosomatid
protozoan Leishmania tarentolae,” Biotechnology and Applied
Biochemistry, vol. 48, no. 1, pp. 55–61, 2007.
[19] C. Heussen and E. B. Dowdle, “Electrophoretic analysis of
plasminogen activators in polyacrylamide gels containing
sodium dodecyl sulfate and copolymerized substrates,” Ana-
lytical Biochemistry, vol. 102, no. 1, pp. 196–202, 1980.
[20] A.-J. van Zonneveld, H. Veerman, and H. Pannekoek, “On the
interaction of the ﬁnger and the kringle-2 domain of tissue-
type plasminogen activator with ﬁbrin. Inhibition of kringle-
2 binding to ﬁbrin by ε-amino caproic acid,” The Journal of
Biological Chemistry, vol. 261, no. 30, pp. 14214–14218, 1986.
[21] M. Nesheim, J. C. Fredenburgh, and G. R. Larsen, “The
dissociation constants and stoichiometries of the interactions
of Lys-plasminogen and chloromethyl ketone derivatives of
tissue plasminogen activator and the variant Δ FEIX with
intact ﬁbrin,” The Journal of Biological Chemistry, vol. 265, no.
35, pp. 21541–21548, 1990.
[22] D. L. Higgins and G. A. Vehar, “Interaction of one-chain
and two-chain tissue plasminogen activator with intact and
plasmin-degraded ﬁbrin,” Biochemistry, vol. 26, no. 24, pp.
7786–7791, 1987.
[23] D. J. Green George, “puriﬁed type I and type II t-PA,” US
Patent WO 89/09820, 1989.
[24] U. Kohnert, R. Rudolph, J. H. Verheijen et al., “Biochem-
ical properties of the kringle 2 and protease domains are
maintained in the refolded t-PA deletion variant BM 06.022,”
Protein Engineering, vol. 5, no. 1, pp. 93–100, 1992.
[25] J.M.A.Manosroi,“Methodsforlargescaleproteinproduction
in prokaryotes,” WO/2002/040696, 2002.
[26] G. N. Levine, M. N. Ali, and A. I. Schafer, “Antithrombotic
therapy in patients with acute coronary syndromes,” Archives
of Internal Medicine, vol. 161, no. 7, pp. 937–948, 2001.
[27] E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J.
A. Cairns, and J. W. Kennedy, “Intravenous thrombolysis in
acute myocardial infarction,” Chest, vol. 119, supplement 1,
pp. 253S–277S, 2001.
[28] D. Russell, K. P. Madden, W. M. Clark, and J. A. Zivin, “Tissue
plasminogenactivatorcerebrovascularthrombolysisinrabbits
is dependent on the rate and route of administration,” Stroke,
vol. 23, no. 3, pp. 388–393, 1992.
[29] E. Topol, R. Caliﬀ, F. Van de Werf et al., “An international
randomized trial comparing four thrombolytic strategies for
acute myocardial infarction,” The New England Journal of
Medicine, vol. 329, no. 10, pp. 673–682, 1993.
[30] D. Collen, “Towards improved thrombolytic therapy,” The
Lancet, vol. 342, no. 8862, pp. 34–36, 1993.
[31] N. Bhana and C. M. Spencer, “Lanoteplase,” BioDrugs, vol. 13,
no. 3, pp. 217–224, 2000.
[32] K. Ouriel, B. Katzen, M. Mewissen et al., “Reteplase in the
treatment of peripheral arterial and venous occlusions: a pilot
study,” Journal of Vascular and Interventional Radiology, vol.
11, no. 7, pp. 849–854, 2000.
[33] A. Klausner, “Researchers probe second generation t-PA,”
Biotechnology, vol. 4, pp. 706–711, 1986.
[34] G. Noll, B. Lammle, and F. Duckert, “Treatment with
stanozolol before thrombolysis in patients with arterial occlu-
sions,” Thrombosis Research, vol. 37, no. 4, pp. 529–532, 1985.
[35] L. Q. L. Pierard, “Secretion of recombinant hybrid plasmino-
gen activator by mouse myeloma cells,” in Advances in Animal
Cell Biology and Technology for Bioprocesses,R .E .S p i e r ,J .B .
Griﬃths, J. Stephenne, and P. J. Crooy, Eds., pp. 475–480,
Butterworths, London, UK, 1989.
[36] T. Cartwright, “Production of t-PA from animal cell culture,”
in Animal Cell Biotechnology,R .E .S p i e r ,J .B .G r i ﬃths, J.
Stephenne, and P. J. Crooy, Eds., pp. 217–245, Academic Press,
New York, NY, USA, 1992.
[37] S. A. Rouf, M. Moo-Young, and Y. Chisti, “Tissue-type
plasminogen activator: characteristics, applications and pro-
ductiontechnology,”BiotechnologyAdvances,v ol.14,no .3,pp .
239–266, 1996.
[38] P. Bagchi, M. Mahesh, and R. Somashekhar, “Pharmaco-
informatics: homology modelling of the target protein (GP1,
2) for Ebola hemorrhagic fever and predicting an Ayurvedic
remediation of the disease,” Journal of Proteomics and Bioin-
formatics, vol. 2, no. 7, pp. 287–294, 2009.Journal of Biomedicine and Biotechnology 9
[39] A.Upshall,A.A.Kumar,M.C.Baileyetal.,“Secretionofactive
human tissue plasminogen activator from the ﬁlamentous
fungus Aspergillus nidulans,” Bio/Technology, vol. 5, no. 12,
pp. 1301–1304, 1987.
[40] R. V. Datar, T. Cartwright, and C.-G. Rosen, “Process
economics of animal cell and bacterial fermentations: a
case study analysis of tissue plasminogen activator,” Nature
Biotechnology, vol. 11, no. 3, pp. 349–357, 1993.
[41] A. Lubiniecki, R. Arathoon, G. Polastri, et al., “Selected
strategies for manufacture and control of recombinant tissue
plasminogenactivatorpreparedfromcellculture,”inAdvances
in Animal Cell Biology and Technology for Bioprocesses,R .E .
Spier, J. B. Griﬃths, J. Stephenne, and P. J. Crooy, Eds., pp.
442–451, Butterworths, London, UK, 1990.
[42] J. F. Lemontt, C. M. Wei, and W. R. Dackowski, “Expression of
active human uterine tissue plasminogen activator in yeast,”
DNA, vol. 4, no. 6, pp. 419–428, 1985.
[43] J. B. Griﬃths and A. Electricwala, “Production of tissue
plasminogen activators from animal cells,” Advances in Bio-
chemical Engineering, vol. 34, pp. 147–166, 1987.
[44] J. Manosroi, C. Tayapiwatana, F. G¨ otz, R. G. Werner, and
A. Manosroi, “Secretion of active recombinant human tissue
plasminogen activator derivatives in Escherichia coli,” Applied
andEnvironmentalMicrobiology,vol.67,no.6,pp.2657–2664,
2001.
[45] Y. Chisti and M. Moo-Young, “Separation techniques in
industrial bioprocessing,” Journal Institution of Chemical Engi-
neers Symposium Series, vol. 137, pp. 135–146, 1994.
[46] X. Li, Y. Qiu, Y. Shen et al., “Splicing together diﬀerent regions
of a gene by modiﬁed polymerase chain reaction-based site-
directed mutagenesis,” Analytical Biochemistry, vol. 373, no. 2,
pp. 398–400, 2008.
[47] P. Elliott, A. Hohmann, and J. Spanos, “Protease expression
in the supernatant of Chinese Hamster Ovary cells grown in
serum-free culture,” Biotechnology Letters, vol. 25, no. 22, pp.
1949–1952, 2003.
[48] GMM Opdenakker, Protease inhibitors, a DNA construct for
t h ee x p r e s s i o no fap r o t e a s ea n dap r o c e s sf o rm e a s u r i n g
proteases and/or protease inhibitors, EP0736302, 1996.